Adagio Medical Holdings, Inc. is a medical device company developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. A standalone PFA console connected to a cryoablation console for PFCA treatment synchronization is used in conjunction with Cryopulse catheter. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for treatment of the ventricular arrhythmia. Its product offerings consist largely of the single use ablation catheters and consoles.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 218.52% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 602.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 602.00K.
Overvalued
The company’s latest PE is -0.22, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 12.12M shares, decreasing 24.43% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 21.67K shares of this stock.